Study shows improved hand function using Carbonhand
STOCKHOLM, March 13, 2024 /PRNewswire/ -- Today, a study on Improved physical function using a power-enhancing glove in persons with Inclusion Body Myositis was presented at the Global Conference on Myositis in Pittsburgh, USA. The preliminary results show increased hand function and... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2024 Category: Pharmaceuticals Source Type: news

UCI awarded 5-year, $4.2M grant to study rare muscle disorder affecting aging Americans
(University of California - Irvine) The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), which affects aging adults causing asymmetric muscle weakness and severe disability. The disease is currently untreatable and poorly understood. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news

Peter Frampton opens up about muscle-wasting disease - and reveals he SLEEPS with his guitar
The 'Baby I Love Your Way' singer Peter Frampton was diagnosed with Inclusion Body Myositis (IBM) four years ago after he suffered a fall on stage and couldn't get up. (Source: the Mail online | Health)
Source: the Mail online | Health - November 27, 2019 Category: Consumer Health News Source Type: news

Biochemical switches identified that could be triggered to treat muscle, brain disorders
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists have found that the enzymes ULK1 and ULK2 play a key role in breaking down cell structures called stress granules, whose persistence leads to toxic buildup of proteins that kill muscle and brain cells. Such buildup is central to the pathology of three related diseases: inclusion body myopathy (IBM), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 10, 2019 Category: International Medicine & Public Health Source Type: news

Researchers identify potential treatment for type of muscle and brain degenerative disease
In fruit flies modeled with IBMPFD disease, mitochondria (red circles) are severely disrupted. Treatment of VCP inhibitors in these diseased flies reversed  mitochondrial damage (green circles). FINDINGSUCLA researchers have discovered the molecular basis of, and identified potential treatment for, an incurable disease known as inclusion body myopathy, Paget disease with frontotemporal dementia, or IBMPFD. Using both genetically engineered fruit flies that have the fly equivalent of the disease gene as well as cells from people with IBMPFD, the researchers discovered how mutations carried by those with IBMPFD cause cellu...
Source: UCLA Newsroom: Health Sciences - March 21, 2017 Category: Universities & Medical Training Source Type: news

Potential treatment for type of muscle and brain degenerative disease
Researchers have discovered the molecular basis of an incurable disease known as inclusion body myopathy, explains a new report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 21, 2017 Category: Science Source Type: news

Researchers identify potential treatment for type of muscle and brain degenerative disease
(University of California - Los Angeles) UCLA researchers have discovered the molecular basis of an incurable disease known as inclusion body myopathy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2017 Category: Global & Universal Source Type: news

Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis
Milo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration ’s (FDA) Office of Orphan Products Development for treatment of inclusion body myositis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 5, 2016 Category: Pharmaceuticals Source Type: news

New drug shows promise against muscle wasting disease
A new drug to treat the muscle wasting disease inclusion body myositis reverses key symptoms in mice and is safe and well-tolerated in patients, finds a new study led by the Medical Research Council Centre for Neuromuscular Diseases at University College London. (Source: Medical Research Council General News)
Source: Medical Research Council General News - March 24, 2016 Category: Research Source Type: news

Misdiagnosis of Inclusion Body MyositisMisdiagnosis of Inclusion Body Myositis
As these cases demonstrate, correct diagnosis of sporadic inclusion body myositis is challenging, often resulting in mis-diagnosis, inappropriate therapies, and unnecessary fears. Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New compound BYM338 could reverse loss of muscle mass in cancer and other diseases
A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease (COPD), sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology."Age-related loss of muscle mass is a major contributing factor to falls, broken bones, and the loss of mobility," says co-corresponding author David Glass of Novartis, Cambridge, MA, one of the compound's developers, along with first author Estelle Trifilieff, also of Novartis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

New compound could reverse loss of muscle mass in cancer and other diseases
(American Society for Microbiology) A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 19, 2013 Category: Global & Universal Source Type: news

Frequency and circumstances of falls in people with inclusion body myositis: A questionnaire survey to explore falls management and physiotherapy provision - Hiscock A, Dewar L, Parton M, Machado P, Hanna M, Ramdharry G.
OBJECTIVES: To survey the incidence and circumstances of falls for people with inclusion body myositis (IBM) in the UK, and to investigate the provision of physiotherapy and falls management. DESIGN: Postal questionnaire survey. SETTING: Participants compl... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - December 17, 2013 Category: Global & Universal Tags: Falls Source Type: news

FDA breakthrough therapy designation for bimagrumab
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM). You must sign in to continue reading this article Hide related content:  Show related content read more (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 22, 2013 Category: Drugs & Pharmacology Authors: mz_loader Tags: *** Editor's Pick Latest News Source Type: news

FDA breakthrough therapy designation for bimagrumab
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM). (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 21, 2013 Category: Drugs & Pharmacology Source Type: news